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Abstract
Common carotid intima-media thickness (cIMT) is an index of subclinical atherosclerosis that is associated with ischemic 
stroke and coronary artery disease (CAD). We undertook a cross-sectional epigenome-wide association study (EWAS) of 
measures of cIMT in 6400 individuals. Mendelian randomization analysis was applied to investigate the potential causal 
role of DNA methylation in the link between atherosclerotic cardiovascular risk factors and cIMT or clinical cardiovascular 
disease. The CpG site cg05575921 was associated with cIMT (beta = −0.0264, p value = 3.5 ×  10–8) in the discovery panel 
and was replicated in replication panel (beta = −0.07, p value = 0.005). This CpG is located at chr5:81649347 in the intron 
3 of the aryl hydrocarbon receptor repressor gene (AHRR). Our results indicate that DNA methylation at cg05575921 might 
be in the pathway between smoking, cIMT and stroke. Moreover, in a region-based analysis, 34 differentially methylated 
regions (DMRs) were identified of which a DMR upstream of ALOX12 showed the strongest association with cIMT (p 
value = 1.4 ×  10–13). In conclusion, our study suggests that DNA methylation may play a role in the link between cardiovas-
cular risk factors, cIMT and clinical cardiovascular disease.
Keywords Epigenome-wide association studies · Differentially methylated regions · DNA methylation · Common carotid 
intima-media thickness · Cardiovascular risk factors · Vascular outcomes · Mendelian randomization
Introduction
Carotid intima-media thickness (cIMT) is defined as a pro-
gressive thickening of the arterial wall and is characterized 
by the presence of large arterial wall deposits. Hemodynamic 
changes leading to atherosclerotic plaques in both carotid and 
coronary arteries including lumen diameter, blood flow, shear 
stress, and tensile stress [1, 2]. Aetiological similarities in car-
diovascular outcomes are also influenced by risk factors such 
as age, blood pressure, blood lipid and fasting plasma glucose 
which are independent predictors of carotid atherosclerosis 
[3, 4]. Evidence suggests that cIMT may be implicated as an 
intermediate factor in the causal pathway leading to cardio-
vascular disease [5] and can be used as a predictor of CAD 
and stroke. Ultrasound of the carotid artery is widely used as 
a non-invasive procedure to detect the presence of atheroscle-
rotic plaques and as a marker of subclinical vascular disease 
[6]. A cIMT value above 75th percentile threshold for a per-
son’s age, sex and race in asymptomatic individuals is associ-
ated with risk of myocardial infarction, stroke and death from 
CAD is significantly increased as compared to the average of 
the population [7]. The addition of cIMT to the Framingham 
Risk Score has been shown to improve the 10-year risk predic-
tion of myocardial infarction or stroke independent of age, sex 
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and cardiovascular risk factors [8]. Therefore, cIMT could add 
considerable utility to the study of the onset and progression 
of atherosclerosis [6].
Epigenetic modifications including covalent changes of 
DNA methylation and chromatin alterations, are known to 
determine genomic structure and to induce changes in the reg-
ulation of gene expression [9]. DNA methylation is considered 
as the most stable epigenetic mark and the most investigated 
in explaining gene expression patterns and cell differentiation. 
DNA methylation varies with age, sex and environmental fac-
tors including diet and smoking [10]. In recent years, there has 
been a growing interest in identifying whether DNA meth-
ylation variations contribute to the onset and progression of 
complex human diseases; accumulating evidence suggests that 
this is the case at least for some traits and disorders [11–15].
Technological advances and the implementation of epig-
enome-wide association study (EWAS), have facilitated the 
systematic assessment of DNA methylation signatures, leading 
to the identification of novel mechanisms related to human 
diseases [16–18]. Epigenomic profile characterized by EWAS 
has been assessed mainly in leukocytes since this is the most 
accessible tissue in epidemiologic studies. Although the sam-
pling of the cell type mediating the disease allows more valid 
casual inference, it has been shown that the use of leukocytes, 
a more accessible surrogate cell type, yields useful information 
[12]. Given the established role of inflammation in develop-
ment of CVD, differences in leucocyte DNA methylation pat-
terns in healthy persons vs. those at risk could either reflect the 
cumulative effects of CVD risk factors or indicate the changes 
the leucocytes undergo in the course of developing CVD. The 
latter might be mimicking or reflect similar processes in vas-
cular cells.
We assessed the association between DNA methylation 
markers and cIMT among over 6,000 European ancestry par-
ticipants using data from eight cohorts participating in the 
Cohorts for Heart and Aging Research in Genomic Epide-
miology (CHARGE) consortium. The analysis of epigenetic 
markers in relation to cIMT could provide insight into mecha-
nisms related to arterial thickness and atherosclerotic disease. 
In addition, we analyzed and characterized differentially 
methylated regions (DMR) of the genome at which adjacent 
CpG sites show differential methylation levels across multiple 
samples. Information from multiple nearby methylation sites 
may aid biological inference as well as increase the power to 
detect associations with human traits [19].
Methods
Study population
Figure 1 depicts an overview of the study flow. This study 
was conducted using data from eight cohorts within the 
Cohorts for Heart and Aging Research in Genomic Epi-
demiology (CHARGE) consortium, an international col-
laborative effort to facilitate collaborative efforts in omics 
era, providing opportunities for meta-analysis and repli-
cation among multiple studies [20]. The discovery panel 
comprised of 6407 subjects from Framingham Heart Study 
(FHS) (n = 1977, mean age ± SD = 66.2 ± 8.9), Cooperative 
Health Research in the Region Augsburg (KORA) (n = 1511, 
mean age ± SD = 60.7 ± 8.9), the Rotterdam Study (RS) 
(first visit of the third sub-cohort RSIII-1 (n = 731, mean 
age ± SD = 59.8 ± 8.2) and third visit of the second sub-
cohort, RSII-3 (n = 468, mean age ± SD = 71 ± 3.2), MRC 
National Survey of Health and Development (NSHD) 
(n = 600, mean age ± SD = 53.4 ± 0.2), The Lothian Birth 
Cohorts (LBC) (n = 288, mean age ± SD = 72.1 ± 0.5), 
Study of Health in Pomerania (SHIP) (n = 246, mean 
age ± SD = 51.4 ± 13.8), Young Finns Study (YFS) (n = 191, 
mean age ± SD = 40.3 ± 3.3) and Cardiovascular Health 
Study (CHS) (n = 191, mean age ± SD = 76 ± 5) (Supplemen-
tary Table S1). For the replication panel, we used data from 
RSIII-2 (n = 251, mean age ± SD = 61.1 ± 4.3) (Supplemen-
tary Table S2). We performed a power calculation for the 
replication analysis using the GPower 3.1 tool [21]. Details 
of the participating studies are provided in Supplementary 
Appendix 1a. All participants provided written informed 
consent.
Measurement of cIMT
All studies evaluated the carotid arteries of cohort partici-
pants using B-mode high-resolution ultrasound by trained 
operators. LBC, YFS, KORA, NSHD and SHIP cohorts 
obtained cIMT measurements from the far wall of the carotid 
artery; whereas CHS, FHS, and RS cohorts measured near 
and far walls. cIMT was calculated by averaging the maxi-
mum cIMT of the right and left common carotid artery in the 
mid portion of the visible segment of the arteries in the neck. 
A longitudinal image was used, optimizing the image frame 
to be perpendicular to the arterial wall. We used natural log 
transformation to deal with the skewness of the cIMT meas-
urements. A description of the method employed in cIMT 
measurement by each study is provided in Supplementary 
Appendix 1a.
DNA methylation measurements
Genome-wide DNA methylation profiling was conducted 
using Illumina Infinium BeadChips arrays. The cohorts 
FHS, KORA, RS, LBC, CHS and YFS used the Human-
Methylation450 BeadChip®; which covers approximately 
485,577 methylation sites. SHIP and NSHD employed 
Infinium MethylationEPIC BeadChip ® array, which cov-
ers approximately 850,000 CpG sites across the genome. 
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Beta values, defined as the ratio of intensities between 
methylated and unmethylated CpG alleles were used to 
represent DNA methylation levels. Study-specific data 
pre-processing and quality control methods are outlined 
in Supplementary Table S3.
Epigenome wide association analysis
All studies used linear mixed-effects models to identify 
associations between DNA methylation levels and cIMT. 
Two regression models were conducted. First, DNA meth-
ylation levels at each CpG site were regressed against 
natural-log transformed cIMT with adjustment for age, 
sex, white blood cell proportions (Houseman estimated 
proportions [22]), smoking history, microarray type and 
position (Model 1). Second, body mass index (BMI), 
HDL cholesterol/triglycerides ratio, systolic blood pres-
sure, antihypertensive drug use, lipid lowering drug use 
and prevalent diabetes mellitus were added to the primary 
regression model (Model 2). Further details are provided 
in Supplementary Table S3. All statistical analyses were 
conducted using R [23].
Meta‑analysis of EWAS
Each cohort separately analyzed the EWAS of cIMT. Sub-
sequently, EWAS summary statistics were uploaded to a 
central repository. Prior to their inclusion into the meta-
analysis, all probes on sex chromosomes, non-CpG probes 
and cross-reactive probes were removed as suggested by 
Chen et al.[24]. The total number of probes included in the 
meta-analysis was 473,755. We performed a fixed effect 
inverse variance weighted meta-analysis using METAL [25]. 
A Bonferroni-corrected significance threshold (assuming 
473,755 independent tests): 0.05/nprobes_max = 0.05/473,755 
≈ 1.05 ×  10−7 was used to account for multiple comparisons 
and assumed as indicating epigenome-wide significance.
Differentially methylated regions
The identification of DMR was conducted using Comb-p, 
a python library that combines and calculates the autocor-
relation among adjacent p values found in genomic regions, 
in order to determine statistical significance at region 
level [26]. DMR analyses were conducted in the discovery 
panel and replication was performed in RSIII-2. Detailed 
Fig. 1  An overview of our study including EWAS meta-analysis to 
identify DNA methylation sites associated with carotid intima-media 
thickness, and post-EWAS in silico analyses. FHS Framingham Heart 
Study, KORA Cooperative Health Research in the Augsburg Region 
Study, RS Rotterdam study, NSHD MRC National Survey of Health 
and Development, LBC The Lothian Birth Cohorts, SHIP Study of 
Health in Pomerania, YFS Young Finns Study, CHS Cardiovascular 
Health Study
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description of DMR identification can be found in Supple-
mentary Appendix 1b.
Methylation risk score
A methylation risk score (MRS) was calculated for each par-
ticipant of the Rotterdam Study based on DNA methylation 
patterns of CpGs identified from DMRs. We first developed 
the score in samples from RSIII-2 and RSII-3 and its per-
formance was further tested in RSIII-1. The risk score was 
estimated as:
where Bm is the meta-analyzed effect of each CpG site on 
cIMT and k is the kth CpG. The MRS was calculated for 
each DMR (MRS.DMR) combined. We conducted a linear 
regression model using log-transformed cIMT as dependent 
variable and MRS for each genomic region (MRS.DMR) 
as independent variables adjusted for sex, age and smoking 
history. In the fully adjusted model, cell counts and batch 
effects were added to the fitted linear-mixed model using 
lme4 package [27]. Detailed information of the construction 
of MRS is outlined in Supplementary Appendix 1c.
Integration of DNA methylation, genetic variation 
and gene expression
We examined the association of DNA methylation levels 
at the identified CpGs, with expression levels of their cor-
responding genes (cis-expression quantitative trait methyla-
tion (eQTM)) and genetic variants both in their vicinity, i.e. 
cis- and genome-wide i.e. trans-methylation quantitative 
trait loci (meQTL)using data from 4170 subjects from FHS 
cohort [28] and from five Dutch biobanks (BIOS-BBMRI 
database) (http:// www. genen etwork. nl/ biosq tlbro wser/). Sig-
nificant threshold was set using Bonferroni-correction. For 
CpG-expression analysis, we corrected for 21,238 expres-
sion probes (α = 2.3 ×  10–6 = 0.05/21,238). We also sought 
genetic variants influencing methylation levels of nearby or 
far-away genes.
Functional and regulatory annotation of CpG sites
We used FUMA (Functional Mapping and Annotation of 
Genome-Wide Association Studies) [29] to functionally 
annotate cis-meQTLs. The SNP2GENE function was also 
used to test cis-meQTLs for association with other traits and 
diseases from the GWAS catalogue [30]. As epigenetic sig-
natures are tissue dependent, and our analysis was limited 
in blood samples, we used expression quantitative trait loci 
(cis-eQTL) data from the Genotype-Tissue Expression Pro-










ortal. org/ home/) a platform with available expression data 
on potential target organs (heart tissue, kidney tissue, brain 
tissue, aortic endothelial cells and blood vessels) as well as 
blood cell types (CD4 + macrophages, monocytes).
Mendelian randomization analysis
We implemented a two-sample, two-step Mendelian Ran-
domization (MR) study [31] (Supplementary Figure S1) 
to investigate for evidence of potentially causal relations 
between the identified CpG sites, cardiovascular risk factors 
and the risk of cardiovascular outcomes. First, we investi-
gated whether the identified CpGs are causally affected by 
cardiovascular risk factors. We selected a panel of SNPs 
associated with each trait at a genome-wide level of sig-
nificance (P < 5 ×  10–8) and minor allele frequency > 0.01 as 
genetic instruments using published genome-wide associa-
tion studies. Only studies including individuals of European 
ancestry were considered. We selected 167 genetic instru-
ments for systolic blood pressure (SBP) [32, 33] (Supple-
mentary Table S4), 170 SNPs associated with diastolic 
blood pressure (DBP) [32, 33] (Supplementary Table S5), 
235 SNPs reported for pulse pressure (PP) [32, 33] (Sup-
plementary Table S6), 123 variants associated with smoking 
index [34, 35] (Supplementary Table S7), 101 SNPs for low-
density lipoprotein (LDL) cholesterol [36, 37] (Supplemen-
tary Table S8) and 40 SNPs associated with glucose levels 
[38] (Supplementary Table S9). We included 362 genetic 
variants previously found to be associated with BMI [39] 
(Supplementary Table S10). After adjustment for multiple 
testing using Bonferroni correction, the significance thresh-
old was set at 0.01 taking into account the number of trait 
groups being tested (0.05/5 group traits including smoking, 
blood pressure, cholesterol, glucose and BMI). Second, we 
examined the effect of DNA methylation on cIMT, CAD and 
stroke. We chose instrumental variables for DNA methyla-
tion levels at c905575921 based on methylation quantitative 
trait loci (meQTL) obtained from FHS cohort (N = 4170) 
Details are described in Supplementary Methods and the list 
of instruments are presented in Supplementary Table S11 
[28]. For step 2, we applied multiple testing correction based 
on three traits being evaluated and the p value threshold was 
set as 0.02. We used MR-PRESSO (Mendelian randomiza-
tion pleiotropy residual sum and outlier) to identify horizon-
tal pleiotropic outliers in multi-instrument summary-level 
MR testing (https:// github. com/ rondo lab/ MR- PRESSO) 
[40]. All MR methods for multiple genetic instruments 
were conducted using “MendelianRandomization”, a sta-
tistical package running under R (https:// cran. rproj ect. org/ 
web/ packa ges/ Mende lianR andom izati on/ index. html) [41]. 
Detailed description of MR methods is outlined in Supple-
mentary Appendix 1.d.
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Results
Baseline characteristics of the nine discovery cohorts 
(n = 6157) and the replication cohort (n = 251) are pre-
sented in supplementary Tables S1 and S2. The sample 
sizes ranged from 191 to 1,977 individuals, all of Euro-
pean ancestry. Approximately half of participants were 
female, ranging from 47.6 to 62%. Mean ± SD age ranged 
from 40.3 ± 3.3 to 76.1 ± 5.1 years.
The quantile–quantile (QQ) plots were generated and 
corresponding lambda values computed for the over-
all meta-analysis of the discovery and replication pan-
els combined, indicated no statistical inflation in Model 
2. Figure 2 shows the Manhattan plot for the discovery 
meta-analysis of the model adjusted for age, sex, techni-
cal covariates, cell counts, smoking status, BMI, HDLC/
TC ratio, SBP, antihypertensive and lipid lowering drugs 
and diabetes. There was one CpG associated with cIMT 
below the epigenome-wide-significance threshold (p 
value = 1.05 ×  10−7). The CpG site cg05575921 showed 
the lowest p value = 2.2 ×  10–8 (beta = −0.02, SE = 0.0048), 
and was replicated in RS-III2 with a p value = 0.004 
(beta = −0.08) (Table 1). The cg05575921 CpG is located 
at chromosome 5 position: 81,649,347 in the intron 3 of 
the aryl hydrocarbon receptor repressor (AHRR) gene 
(Fig. 3a, [42]). Meta-analysis performed in smokers and 
non-smokers from Rotterdam Study revealed a stronger 
association between cg05575921 and cIMT in smokers, 
in comparison to non-smokers (smokers: beta = −0.07, 
p value = 8.1 ×  10–5; non-smokers: beta = −0.01, p 
value = 0.2).Further adjustments for additional potential 
confounders including BMI, HDL cholesterol/triglycer-
ides ratio, systolic blood pressure, antihypertensive and 
Fig. 2  Manhattan plot Epigenome wide association between genome-wide DNA methylation and carotid intima media thickness
Table 1  CpG sites significantly 
associated with CIMT in 
discovery panel and replication 
study
*First model: BETA ~ Ln(cIMT) + age + sex + tech cov + cell counts + smoking status (+ study specific)
**Second model: BETA ~ Ln(cIMT) + age + sex + tech cov + cell counts + smoking status (+ study spe-
cific) + BMI + HDLC/TC ratio + SBP + antihypertensive + lipid lowering + pDM.
CpG site Position Gene Discovery Panel Replication study Combined analysis
Beta p value Beta p value Beta p value
cg05575921* Chr5:373378 AHRR − 0.02 3.5 ×  10−8 − 0.07 0.005 − 0.03 3.17 ×  10−9
cg05575921** Chr5:373378 AHRR − 0.02 2.2 ×  10−8 − 0.08 0.004 − 0.03 1.9 ×  10−9
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lipid lowering drug use, prevalent and diabetes mellitus 
did not substantially change the effect estimates and p 
values in both the discovery panel (p value = 2.2 ×  10–8, 
beta = −0.02) and replication cohort (p value = 0.004, 
beta = −0.08) (Table 1). Furthermore, sensitivity analysis 
including hypertensive disease in the fully adjusted model 
showed no different result in comparison with Model 2.
In the discovery panel, we identified 34 DMRs, composed 
of 247 CpGs, associated with cIMT. The strongest asso-
ciation (p value = 1.4 ×  10–13) was observed in a cluster of 
12 CpG sites annotated to the promoter region of ALOX12 
(in the upstream genomic region of chromosome 17 posi-
tion: 6,899,085 to 6,899,759) (Supplementary Table S12, 
Fig. 3b). Most of the CpG sites clustered in these DMRs 
were annotated to the promoter region or transcription site 
of a close by genes. However, none of these DMRs were rep-
licated in RSIII-2. To assess the variance of cIMT explained 
by these DMRS, we calculated a methylation risk score 
using 247 CpG sites. Fully adjusted linear regression mod-
els showed that MRS, which was developed in RSIII-2 and 
RSII-3, explained a small proportion of the cIMT variance 
(4.4%, p value = 2.2 ×  10–16) observed in RSIII-1.
We further investigated the role of the methylation sta-
tus in cg05575921 on gene expression levels measured in 
subjects from FHS. We found 285 gene expression mark-
ers associated with cg05575921 in cis and trans eQTM 
(Supplementary Table S13). The strongest association was 
found for the transcripts of the LRRN3 (Leucine Rich Repeat 
Neuronal 3) gene. Hypermethylation status of cg05575921 
was negatively correlated LRRN3 (p value = 1.9 ×  10–100). 
In the look-up for cis-eQTM in the BIOS-BBMRI dataset, 
cg05575921 was associated with expression levels of EXOC3 
(exocyst complex component 3) (p value = 1.2 ×  10–6). These 
gene expression markers were not associated with cIMT, as 
measured in RSIII-1. Moreover, cg05575921 was associated 
with 116 genetic variants in the neighbouring genes includ-
ing AHRR, CCDC127, LRRC14B, PDCD6, PLEKHG4B and 
SDHA (cis-meQTLs) (Supplementary Table S14). A heat-
map depicting average expression of these 6 genes across 53 
human tissues, available on the "Functional Mapping and 
Annotation of genetic associations with FUMA" webtool 
is provided in the Supplementary Figure S2. Based on the 
tissue specificity of differential expression using GTEXT, a 
total of 3,588 expression quantitative trait loci (eQTLs) in 
AHRR have been reported in several tissues, predominantly 
in brain (Supplementary Table S15, Supplementary Figure 
S3).
Mendelian randomization
We applied a two-step Mendelian randomization analysis to 
investigate whether DNA methylation mediates the effect 
Fig. 3  a Genomic location of cg05575921. b Genomic location of CpGs annotated to DMR ALOX 12 
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of traditional CVD risk factors on cardiovascular diseases. 
First, we studied the causal effect of cardiovascular risk 
factors on DNA methylation at cg05575921. Results from 
the conventional and sensitivity MR analyses are shown 
in Tables  2 and 3. MR estimates showed that smoking 
might have an effect on DNA methylation at cg05575921 
(IVW·beta = −0.04, p value = 0.0001; Supplementary Fig-
ure S4). In contrast, MR estimates did not support an effect 
for LDL (IVW·beta = 0.002, p value = 0.4; Supplemen-
tary Figure S5), SBP (IVW·beta = −0.001, p value = 0.06; 
Supplementary Figure S6), DBP (IVW·beta = −0.001, 
p value = 0.3; Supplementary Figure S7), pulse pressure 
(IVW·beta = 0.0001, p value = 0.9; Supplementary Figure 
S8), glucose (IVW·beta = −0.01, p value = 0.3; Supplemen-
tary Figure S9) or BMI (IVW·beta = −0.008, p value = 0.07; 
Supplementary Figure S10). Second, we assessed whether 
there is any evidence for shared causal genetic variants 
between DNA methylation at cg05575921, cIMT, CAD 
and stroke. We identified 3 independent genetic instru-
ments for this CpG site (p values < 5 ×  10–8,  R2 < 0.25). 
Only two out of the three genetic instruments were present 
in the meta-analysis of GWAS on CAD and no proxies have 
been reported for the absent SNP. We found that methyla-
tion at cg05575921 has a potential causal effect on cIMT 
(IVW·beta = 0.06, p value = 0.01; Supplementary Figure 
S11) and stroke (IVW·beta = 0.8, p value = 0.007; Sup-
plementary Figure 12) but not on CAD (IVW·beta = 0.5, p 
value = 0.07).
Discussion
This study is the first epigenome wide association study 
on cIMT, an index of atherosclerosis. We report differen-
tial DNA methylation at one CpG site and 34 DMRs as 
associated with cIMT. The association found for the CpG 
cg05575921 was independent of potential confounders 
including BMI, lipid traits, blood pressure and smoking. 
The CpG sites found in DMRs combined in a methylation 
risk score, explained up to 4.4% of the variance observed 
in cIMT in European population. In addition, we found that 
DNA methylation at cg05575921 is implicated in the path-
way between smoking, cIMT and stroke using Mendelian 
randomization analysis.
Our top hit is in the intronic region of the AHRR gene, 
located on chromosome 5 which is believed to possess sev-
eral tumor suppressor genes [43, 44]. This gene encodes 
aryl-hydrocarbon receptor repressor, a protein that partici-
pates in the aryl hydrocarbon receptor (AhR) signaling cas-
cade, which mediates the metabolism of xenobiotic particles 
like toxic cigarette smoke components [45, 46]. It functions 
as a feedback modulator by repressing AhR-dependent gene 
expression [47] and is also involved in regulation of cell 
growth and differentiation. While there is no clear mechanis-
tic role of AHRR in atherogenesis, it is believed that numer-
ous agonists of AhR signaling are contained in tobacco 
smoking and persistent activation of this signaling pathway 
may contribute to atherogenesis. Wu et al., showed that the 
treatment of macrophages with 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD) [46] leads to AhR–dependent activation 
of inflammatory mediators and atherosclerotic plaque for-
mation [48]. In addition, Vogel et al. demonstrated that 
TCDD promotes the differentiation of U937 macrophages 
to atherogenic foam cells, verified by lipid accumulation and 
extensive formation of blebs on the cell surface, which are 
characteristics of foam cells [49]. Meta-analysis performed 
in smokers and non-smokers from Rotterdam Study revealed 
a stronger association between cg05575921 and cIMT in 
smokers, in comparison to non-smokers. Based on our find-
ings, smoking might explain the association described in 
this study We suggest the inclusion of more comprehensive 
covariates for smoking behavior (eg. Number of cigarettes 
per day, number of smoking years, passive smoking, etc.) in 
the modelling of DNA methylation-cIMT association.
We also observed an inverse association between DNA 
methylation of cg05575921 and levels of 285 mRNA expres-
sion probes, in which the majority are transcripts of inflam-
mation genes. These findings suggest that increased meth-
ylation at AHRR gene decreases expression of relevant genes 
that are critical in the regulation of the inflammatory mecha-
nisms taking place in the vascular wall. In our study, LRRN3 
gene showed the strongest association with methylation of 
cg05575921. The LRRN3 has been shown to be differentially 
expressed between regions of plaque rich in smooth muscle 
cells and macrophages [50]. Furthermore, LRRN3 has been 
incorporated in predictive models in whole blood to evalu-
ate self-reported smoking status (current and recently quit 
smokers vs. former and never smokers) [51]. Based on our 
findings, the differentially expressed genes associated with 
cg05575921 could compromise downstream signals, result-
ing in the variability observed for cIMT in this population.
We also implemented bioinformatics tools to evaluate 
the presence of differentially methylated regions which 
are genomic regions with adjacent CpG islands that show 
differential methylation [19].The identification of DMRs 
is thought to provide a more comprehensive characteriza-
tion of a genomic region based on the analysis of corre-
lated CpGs [52]. In this study, the assessment of DMRs 
allowed us to identify associations of target genomic 
regions with cIMT. Among the regions identified, the 
strongest association was observed for ALOX12. Further-
more, significant associations were observed for 33 addi-
tional DMRs, including AHRR, located in genes involved 
in molecular mechanisms of cell signaling, vascular func-
tion and inflammation. ALOX12 encodes a member of the 
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lipoxygenase family of proteins. Lipoxygenases (LOXs) 
are dioxygenases that catalyze the formation of corre-
sponding hydroperoxides from polyunsaturated fatty acids 
such as linoleic acid and arachidonic acid [53]. These bio-
active lipid mediators are thought to exert potent actions 
on inflammatory reactions related to several cardiovascu-
lar diseases, such as atherosclerosis [54]. Polymorphisms 
in ALOX12 have shown to be genetically associated with 
subclinical atherosclerosis and with biomarkers of disease 
in families with type 2 diabetes [55]. Mice models lacking 
ALOX12 (P-12LO) exhibit a selective modulatory role for 
P-12LO in the ADP-induced pathway of platelet aggrega-
tion in mice, and increased mortality in an ADP-induced 
mouse model of thromboembolism [56]. Lipoxygenases, 
especially ALOX12 may be considered as an interesting 
new genomic target for further investigations on traits 
related to vascular inflammation and impaired vascular 
function. Although these regions were not replicated on 
an independent sample, the genes identified have biologic 
relevance on the trait. The limited sample size of the rep-
lication cohort may have contributed to the lack of repro-
ducibility of our findings.
Table 2  Mendelian 
randomization analysis on the 
effect of cardiovascular risk 
factors on cg05575921
BMI body mass index, CAD coronary artery disease, cIMT carotid intima media thickness, IVW inverse 
variance weighted, LDL low-density lipoprotein
Method Estimate (95% CI) p value p value 
heterogeneity 
(IVW)
Smoking (no. cigarettes/day) → cg05575921
 IVW − 0.04 (− 0.09 to 0.06) 0.0001 0.9
 MR-Egger − 0.06 (− 0.39 to −0.27) 0.08 –
 MR-Egger (intercept) 0 0.5 –
 Weighted median − 0.04 (− 0.18 to 0.05) 0.08 –
LDL-cholesterol (mg/dl−1) → cg05575921
 IVW 0.002 (− 0.02 to 0.02) 0.4 0.9
 MR-Egger 0.0001 (− 0.05 to 0.02) 0.9 –
 MR-Egger (intercept) 0 0.5 –
 Weighted median 0.003 (− 0.05 to 0.01) 0.4 –
Systolic blood pressure (mm Hg) → cg05575921
 IVW − 0.001 (− 0.005 to 0.003) 0.06 0.4
 MR-Egger 0.004 (− 0.01 to 0.01) 0.04 –
 MR-Egger (intercept) − 0.001 0.006 –
 Weighted median − 0.001 (− 0.008 to 0.004) 0.2 –
Diastolic blood pressure (mm Hg) → cg05575921
 IVW − 0.001 (− 0.008 to 0.003) 0.3 0.8
 MR-Egger 0.001 (0.026–0.07) 0.8 –
 MR-Egger (intercept) 0 0.6 –
 Weighted median − 0.001 (− 0.01 to 0.007) 0.6 –
Pulse pressure (mm Hg) → cg05575921
 IVW 0.0001 (0.0001–0.002) 0.9 0.9
 MR-Egger 0.0001 (0.0003–0.003) 0.8 –
 MR-Egger (intercept) 0 0.8 –
 Weighted median − 0.001 (− 0.002 to 0.02) 0.5 –
Fasting glucose (mmol/l) → cg05575921
 IVW − 0.01 (− 0.2 to 0.17) 0.3 0.6
 MR-Egger 0.003 (0.005 to 0.008) 0.9 –
 MR-Egger (intercept) 0 0.6 –
 Weighted median − 0.02 (− 0.3 to 0.2) 0.3 –
BMI (kg/m2) → cg05575921
 IVW − 0.009 (− 0.002 to 0.034) 0.07 0.9
 MR-Egger 0.001 (0.004− 0.008) 0.9
 MR-Egger (intercept) 0 0.4
 Weighted median − 0.009 (− 0.002 to 0.04) 0.2
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The cross-sectional design of our study makes it diffi-
cult to determine whether cardiovascular risk factors are 
confounders or precursors in the reported methylation-
cIMT associations. Causal inference in this setting can be 
addressed by Mendelian randomization methods, which may 
rule out reverse causation and confounding and provides fur-
ther understanding on the direction of risk factor-outcome 
association. We conducted MR analysis addressing the effect 
of cardiovascular risk factors on DNA methylation and the 
effect of DNA methylation on cardiovascular outcomes. 
This enabled us to get a better understanding of the potential 
role of epigenetic markers in mediating the environmental 
impact on complex disease [31]. Results of our Mendelian 
randomization analysis suggest that smoking has a strong 
association on DNA methylation at cg05575921 which 
consecutively is associated with cIMT and stroke. Our MR 
findings strengthens the hypothesis regarding an effect of 
smoking on the methylation of the AHRR gene and its role 
in the mechanistic pathway between tobacco consumption 
and vascular outcomes. On the contrary, no MR association 
was observed for other cardiovascular risk factors included 
in this study. One explanation is that the genetic variants 
included in MR may explain a small proportion of the total 
variance in cardiovascular risk factors and DNA methylation 
status, and this could affect the statistical power to address 
any causal relations. Another explanation is that the risk 
factors do not interfere with the methylation of the CpG, but 
the CpG assists in increase of the risk, eg. by increasing the 
impact of smoking.
This study has several strengths and limitations. The 
major strength is the large sample size as it is thus far the 
largest EWAS meta-analyses exploring the association of 
DNA methylation with cIMT. All contributing cohorts had 
DNA methylation measured in whole blood, and adjust-
ment for cell components allowed us to account for different 
epigenetic markers within cells present in the blood. Recent 
publications support that trait-specific differentially methyl-
ated sites identified in blood can show similar associations 
in the target tissue [33, 57, 58]. This suggests that DNA 
methylation measured in blood can be used as a proxy of 
methylation in vascular tissues, particularly given the estab-
lished role of inflammation in development of atheroscle-
rotic CVD. In addition, we implemented a wide variety of 
resources in the characterization of our findings, including 
gene expression assessment, identification of the effect of 
genetic variants on DNA methylation levels, identification 
of differentially methylated regions and the implementation 
of a comprehensive Mendelian randomization approach.
The findings of this study should be considered in 
light of some limitations. The meta-analysis results were 
obtained by combining DNA methylation results from 
European populations. The exclusion of 117 African-
American (AA) individuals from CHS cohort was based 
on potential differences of DNA methylation patterns 
observed between individuals of AA and European ances-
tries. Indeed, the inclusion of data from non-European 
population led to different results in both single CpG meta-
analysis and DMRs assessment. A sensitivity analysis to 
study the impact of ancestry in the results is a valuable 
approach, however our sample size was limited. There-
fore, other studies are needed to assess the generalizability 
of our findings to other ancestries. Moreover, the causal-
ity results reported through Mendelian randomization 
methods should be addressed with caution. The variance 
explained by several SNPs associated with cg05575921 
was rather small and the estimation of the strength of the 
instrumental variables yielded no suitable instruments for 
this CpG in Mendelian randomization analyses.
In conclusion, we identified one CpG located at AHRR 
to be associated with common carotid intima-media 
Table 3  Mendelian 
randomization on the effect of 
cg05575921 on coronary artery 
disease (CAD), cIMT and stroke




 IVW 0.5 (− 0.03 to 0.9) 0.06 0.8
cg05575921 → cIMT (mm)
 IVW 0.06 (0.01–0.1) 0.01 0.2
 MR-Egger − 0.04 (− 0.2 to 0.09) 0.5 –
 MR-Egger (intercept) 0.003 0.1 –
 Weighted median 0.07 (0.008–0.13) 0.02 –
cg05575921 → Stroke
 IVW 0.8 (0.23–1.47) 0.007 0.8
 MR-Egger 0.3 (− 1.3–1.9) 0.7 –
 MR-Egger (intercept) 0.02 0.5 –
 Weighted median 0.9 (0.17–1.58) 0.01 –
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thickness, a subclinical marker of atherosclerosis. DNA 
methylation at ALOX12 and other 33 DMRs also contrib-
ute to the phenotype. Furthermore, DNA methylation of 
AHRR gene might be implicated in the causal pathway 
between smoking, cIMT and stroke. Epigenetic changes 
may be useful as biomarkers of collective and accumu-
lated exposures and diseases and when casual, as tar-
gets for modification through preventive and therapeutic 
interventions. The findings of our study could also have 
implications for prevention and treatement, however, we 
emphasize that our findings were modest in size and for 
the therapeutic use, the causality should be further studied 
including animal models, longitudinal studies of exposure-
discordant monozygotic twins; and paying close attention 
to windows of vulnerability, environmental and nutritional 
assessment, and cell type-specific epigenetic patterns [59, 
60].
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